Medicine and Dentistry
COVID-19
100%
COVID-19 Therapy
71%
Severe Acute Respiratory Syndrome Coronavirus 2
31%
Tocilizumab
28%
Artificial Respiration
20%
Human Epididymis Protein 4
14%
Cerebral Sinus Thrombosis
14%
Care Group
14%
Neoplasm
14%
Paclitaxel
14%
Endometrial Cancer
14%
Fumaric Acid Dimethyl Ester
14%
Anakinra
14%
Cancer Cell
14%
Breast Cancer
14%
Empagliflozin
14%
Drug Megadose
14%
Atypical Hyperplasia
14%
Biological Marker
14%
Acetylsalicylic Acid
14%
In Vitro
14%
Motor Neuron Disease
14%
Proopiomelanocortin
14%
TDP 43 Proteinopathy
14%
Immunoglobulin
14%
Serositis
14%
Azithromycin
14%
Levonorgestrel
14%
Small Cell Lung Cancer
14%
Frontotemporal Lobar Degeneration
14%
Tau
14%
Hypoxia
11%
Intention-to-Treat Analysis
10%
Methylprednisolone
9%
Monoclonal Antibody
7%
Low Drug Dose
6%
Dexamethasone
6%
Omicron Coronavirus Variant
5%
Infusion
5%
Diseases
5%
Progression Free Survival
5%
Corticosteroid
5%
Overall Survival
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
28%
Immunotherapy
28%
Endometrium Cancer
28%
Progression Free Survival
15%
Hyperplasia
14%
Paclitaxel
14%
Breast Cancer
14%
Empagliflozin
14%
Acetylsalicylic Acid
14%
Azithromycin
14%
Biological Marker
14%
Human Epididymis Protein 4
14%
Levonorgestrel
14%
Fumaric Acid Dimethyl Ester
14%
Baricitinib
14%
SARS Coronavirus
14%
Febrile Neutropenia
7%
Endometrium Carcinoma
7%
Janus Kinase Inhibitor
7%
Overall Survival
6%
Inflammation
5%
Nursing and Health Professions
Artificial Respiration
23%
Rate Ratio
19%
Health Care Quality
16%
Empagliflozin
14%
Meta Analysis
14%
Azithromycin
14%
Drug Megadose
14%
Baricitinib
14%
National Health Organization
9%
Intention to Treat Analysis
7%
Randomization
7%
Janus Kinase Inhibitor
7%
Hypoxia
6%
Dexamethasone
6%
Low Drug Dose
6%